H. Sun, D. Sebaratnam
May 18, 2020
Citations
0
Influential Citations
10
Citations
Journal
Clinical and Experimental Dermatology
Abstract
Clascoterone (cortexolone 17α-proprionate) is a novel androgen receptor inhibitor and recent trials reporting its topical use in acne have demonstrated promising results.1 Clascoterone antagonises dihydrotestosterone (DHT) through competitive binding with cytoplasmic androgen receptors as it shares the same fused four-ring backbone structure. Whilst the exact pathogenesis of androgenetic alopecia remains unclear, there is a general consensus that DHT plays a causal role in its development. It therefore stands to reason that topical clascoterone may be efficacious in the treatment of androgen-mediated hair loss as observed in androgenetic alopecia.